8-K ·Filed Apr 29, 2026

AMRN

AMARIN CORP PLC\UK
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001193125-26-188935
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Revenue growth is modest but steady; focus on the Recordati partnership ramp in Europe and potential strategic alternatives. Cash position is strong, reducing bankruptcy risk. Monitor next quarter for sustained revenue growth and progress toward profitability.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
AMRN ▼ -5.18% at T+60d
NEUTRAL call ✗ call lost -5.18% · α vs SPY -9.29% · entry $14.29 → $13.55
Entry anchored
Apr 29, 2026
via day open
T+1d
-2.52%
call -2.52% · α -3.54%
$13.93
settled 5mo ago
T+5d
+4.27%
call +4.27% · α +1.16%
$14.90
settled 5mo ago
T+20d
+0.84%
call +0.84% · α -5.21%
$14.41
settled 4mo ago
T+60d
-5.18%
call -5.18% · α -9.29%
$13.55
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Amarin reported Q1 2026 revenue of $45.1M (+7% YoY), beating the $43.8M consensus, but GAAP EPS was -$0.03, a significant miss vs the $0.17 estimate. Net loss narrowed to $10.5M from $15.7M a year ago, driven by cost cuts. The company reiterated full-year positive cash flow guidance but provided no top-line forecast.

Key Financial Metrics

EPS
$-0.03
Revenue
$45.1M
+7.4% YoY
Gross Margin
39.4%

Key Facts

  • Q1 2026 total net revenue $45.1M, up 7% from $42.0M in Q1 2025
  • GAAP net loss $(10.5)M or $(0.03) per share vs loss of $(15.7)M or $(0.04) in Q1 2025
  • Operating expenses fell 31% to $29.1M, including $3.3M restructuring
  • Cash and investments rose to $307.8M from $302.6M at Dec 2025; debt-free
  • Reiterated expectation for positive cash flow for full year 2026

Financial Impact

Revenue beat consensus by ~3%; EPS miss of ~$0.20 vs consensus

revenueepscashoperating expenses

Risk Factors

  • Generic competition for VASCEPA in the US could pressure market share
  • European sales transition to Recordati may cause near-term volatility
  • Litigation settlements ($3.1M in Q1) may recur

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-188935
Document: amrn-20260429.htm0001193125-26-188935
Document: 0001193125-26-188935-index-headers.html0001193125-26-188935
Document: 0001193125-26-188935-index.html0001193125-26-188935
Document: 0001193125-26-188935.txt0001193125-26-188935
8-K Data (Synthetic)0001193125-26-188935
5 reports for AMRN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AMRN — sortable, filterable
TypeNow
Aug 28, 2026
5w ago
Press Release
NEUTRAL ★ 4/10
$13.97 $13.25▼ −5.15%▼ −5.41%$12.51 (−10.45%)
Jun 4, 2026
17w ago
Court Ruling
BEARISH ★ 7/10
$13.80 $16.37▼ −18.62%▼ −20.00%$12.51 (+9.35%)
Apr 29, 2026
22w ago
8-K
NEUTRAL ★ 4/10
$14.29 $14.41▲ +0.84%▼ −5.21%$12.51 (−12.46%)
Mar 16, 2026
28w ago
Press Release
NEUTRAL ★ 4/10
$15.42 $14.55▼ −5.64%▼ −9.42%$12.51 (−18.87%)
Feb 25, 2026
31w ago
8-K
BEARISH ★ 6/10
$14.05 $14.68▼ −4.48%▼ −9.72%$12.51 (+10.96%)
Showing 5 of 5

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access